Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
✨ Key Finding: Right ventricular maladaptive remodeling and pulmonary arterial uncoupling drive right heart failure, making the right ventricle a central therapeutic target in pulmonary hypertension.
Clinical guidelines summarize CV medication management in noncardiac surgery, highlighting new recommendations.

“Now published in @JAMA_current, our synopsis of preop guidelines by @ACCinTouch @American_Heart https://t.co/313kJCokQU”
✨ Key Finding: Women with breakthrough ischemic stroke on oral anticoagulants for atrial fibrillation had lower rates of return to baseline neurologic function than men (35.2% vs 42.7%; aRR 0.82).
Research identifies molecular targets linked to coronary artery calcification, suggesting pathways for intervention.
✨ Key Finding: Coronary microvascular dysfunction in Takotsubo syndrome contributes to transient left ventricular dysfunction and is associated with an adverse prognosis, including higher mortality.
Observational analysis finds increased heart failure risk linked to poor cardiovascular-kidney-metabolic health in older adults, suggesting significant health implications.
✨ Key Finding: Sacubitril-valsartan did not significantly reduce cardiovascular mortality or HF hospitalization (RR 0.92) compared to enalapril in Chagas cardiomyopathy, despite reducing NT-proBNP by 31%.
✨ Key Finding: COVID-19 recovery is associated with a 35% increased risk of new-onset heart failure (aHR 1.35), particularly among kidney transplant recipients and adults under 65.
✨ Key Finding: Invasive management reduced all-cause mortality by 43.5% (HR 0.565) compared to conservative management in patients aged 60 years and older with NSTEMI.
Virtual clinical trials leverage digital twins to predict and prevent postoperative atrial fibrillation, suggesting major implications for cardiac surgery outcomes.